Matches 101 - 150 out of 248 < 1 2 3 4 5 >


Match Document Document Title
US20100266581 COMPOSITIONS AND METHODS FOR MODULATING S-NITROSOGLUTHIONE REDUCTASE  
Disclosed herein are methods and compositions for modulating the levels and/or activity of S-nitrosoglutathione reductase (GSNOR) in vivo or in vitro. Specifically disclosed are GSNOR deletion...
US20080107646 METHOD FOR AMELIORATING PRURITUS  
A method for preventing, treating, or ameliorating pruritus caused by skin, mucosa, or systemic disorder. The method comprises administering to a subject with pruritus or topically applying to an...
US20150125442 METHODS FOR TREATING MUSCLE SPECIFIC RECEPTOR KINASE MYASTHENIA GRAVIS  
Agents, compositions, and medicaments that reduce interactions between muscle specific kinase receptor (MuSK) and pathogenic immunoglobulin G4 (IgG4) antibodies specific for the first Ig-like...
US20060140930 Promotion of central nervous system remyelination using monoclonal autoantibodies  
Monoclonal IgM antibodies which promote central nervous system remyelination when given to a mammal afflicted with a demyelinating disease are disclosed. These antibodies show multi-organ...
US20060286089 Compositions and methods for the treatment of burns and sepsis  
The present invention relates generally to methods for treating burns and sepsis, in particular for treating immune dysfunction associated with burns and sepsis. The present invention also relates...
US20090060906 Anti-IL-13 antibody formulations and uses thereof  
Formulations suitable for treatment of disorders associated with undesirable expression or activity of IL-13 are provided.
US20070190044 Compositions and methods for manipulating levels of antigen-specific antibodies in a mammal  
The invention provides compositions and methods for increasing the levels of an autoantigen-specific IgM antibody in a mammal and, thus, decreasing the levels of a circulating autoantigen in a...
US20080206237 Synergistic Combination Of Xolair/Omalizumab/E25 With Immunosuppressive Agent  
The present invention provides a pharmaceutical composition comprising an Anti-IgE Antibody and at least one further immunosuppressive agent, in which the active ingredients are present in each...
US20100158899 PROTEIN FORMULATION  
A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for...
US20070292416 De-Immunized Anti-Cd3 Antibody  
Antibodies or functional antibody fragments that recognize or interfere with the production of a component of the CD3 antigen complex are de-immunized.
US20050191290 Means and methods for manipulating hypersensitivity-like responses  
Immunoglobulin light chains (Ig-LC) are produced in excess in animals compared to heavy chains. The present invention implicates Ig-LC in hypersensitivity responses and provides ways for...
US20120100131 METHOD FOR TREATMENT OF BLOOD TUMOR USING ANTI-TIM-3 ANTIBODY  
Disclosed is a therapeutic method comprising administering a TIM-3 antibody to a subject who is suspected to be suffering from blood tumor and in whom TIM-3 has been expressed in a...
US20050181457 FcyrIII signaling inhibitor assay  
The present invention provides an assay and its use for identifying agents that inhibit the FcγRIII signaling.
US20080305038 Transport of Nano-and Macromolecular Structures Into Cytoplasm and Nucleus of Cells  
The present invention refers to novel conjugate molecules and their use or the transport of nano- and macromolecular structures into cells and/or the nucleus. More particularly, the present...
US20150216973 METHOD FOR THE INDUCTION OF AN IMMUNE RESPONSE  
An immune response against an antigen is induced by stimulation with a two-component vaccine that includes an antiidiotypic antibody as one of the components. An immune response against an antigen...
US20050163768 Monoclonal antibodies and their use  
Monoclonal murine internal image anti-idiotypic antibodies (Ab2) to monoclonal antibodies BR55-2 (Ab1), process for the production thereof and use for prophylactic and/or therapeutic immunization...
US20120294850 Ganglioside Epitopes For Treating Guillain-Barre Syndrome  
Disclosed are compositions and methods for treating Guillain-Barré syndrome (GBS) in a subject that involves neutralizing specific pathogenic anti-glycolipid antibodies in the circulation of the...
US20110131669 GANGLIOSIDE EPITOPES FOR TREATING GUILLAIN-BARRE SYNDROME  
Disclosed are compositions and methods for treating Guillain-Barré syndrome (GBS) in a subject that involves neutralizing specific pathogenic anti-glycolipid antibodies in the circulation of the...
US20090275124 Methods and Compositions Comprising Anti-Idiotypic Antibodies to Anti-MMP-14 Antibodies  
Provided are anti-idiotypic antibodies specific for a CDR of an anti-MMP-14 antibody for use as reagents in novel assays for anti-MMP-14 antibodies, pharmaceutical compositions and vaccines.
US20100291070 TYPE III SECRETION SYSTEM COMPONENT PROTEIN PA1698 OF PSEUDOMONAS AERUGINOSA  
An object is to provide an antibody and a vaccine composition which have an ability to practically prevent or treat a Pseudomonas aeruginosa infection, and which can cope with the diversity of...
US20060228306 Combination antihistamine and steroid medication  
The invention provides a topical pharmaceutical composition for application to the nasal or ocular mucosa which comprises (1) a pharmaceutical excipient suitable for topical administration, (2) an...
US20130071353 Antiviral Compounds and Methods of Use Thereof  
Inhibitors of retroviral propagation, methods of treatment and prevention of retroviral infections using the inhibitors, and pharmaceutical compositions including the inhibitors, are disclosed.
US20060062781 Specific ab1'-antibodies against tumour-associated antigen ca 125  
The present invention concerns specific anti-anti-idiotypic antibodies which react with anti-idiotypic antibodies which represent an internal image of the antigen CA125 and which also bind to the...
US20140115729 APOPTOTIC ANTI-IGE ANTIBODIES  
The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.
US20060240000 Combination treatments for allergic disease comprising administering an anti-IgE antibody and antiallergic compound  
Pharmaceutical composition comprising an anti-IgE antibody and at least one further antiallergic compound selected from the group consisting of anti-inflammatory agents, leukotriene modifiers,...
US20090285803 ANTI-PirB ANTIBODIES  
The present invention relates generally to neural development and neurological disorders. The invention specifically concerns identification of novel modulators of the myelin-associated inhibitory...
US20100158898 METHODS OF TREATING IgE-MEDIATED DISORDERS COMPRISING THE ADMINISTRATION OF HIGH CONCENTRATION ANTI-IgE ANTIBODY FORMULATIONS  
The present application relates to methods of treating IgE-mediated disorders comprising the administration of highly concentrated anti-IgE antibody formulations with reduced viscosity that are...
US20070148163 Mutants of anti-cd40 antibody  
A mutant of a potentially therapeutic anti-CD40 antibody is provided which mutant has reduced ADCC and CDC activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic...
US20060263350 Combination antihistamine medication  
The invention provides a topical pharmaceutical composition for application to the nasal or ocular mucosa which comprises (1) a pharmaceutical excipient suitable for topical administration, (2) a...
US20060246056 Immunotherapy of rectal cancer  
Described is the use of an immunotherapeutic agent targeting a human tumor associated antigen for the production of a medicament for immunotherapy of patients with rectal cancer or being at risk...
US20100233158 INDUCTION OF IMMUNE TOLERANCE  
Methods of inducing immune tolerance by administering an immunosuppressive agent and a compound represented by Formula (I) are disclosed: Additionally methods of suppressing an immune response by...
US20110076264 IMMUNOGLOBULIN CLEAVAGE FRAGMENTS AS DISEASE INDICATORS AND COMPOSITIONS FOR DETECTING AND BINDING SUCH  
The invention relates to antibody compositions and use of the composition to detect disease processes associated with elaboration of proteases. The reagents are directed to assessing an IgG...
US20110014187 MONOCLONAL ANTIBODIES CAPABLE OF REACTING WITH A PLURALITY OF INFLUENZA VIRUS A SUBTYPES  
Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A...
US20060078943 Method for obtaining anti-idiotype antibodies  
A method for identifying molecules which mimic an idiotype of an autoimmune disease-associated auto-antibody (autoantibodies). The method comprises the following steps: (a) purifying...
US20090017015 Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders  
The invention relates to the use of a Dipeptidyl peptidase IV inhibitor (DPP-IV inhibitor) or a pharmaceutically acceptable salt thereof for the prevention, delay of progression or the treatment...
US20120148571 AMINO ACID SEQUENCES THAT BIND TO SERUM PROTEINS IN A MANNER THAT IS ESSENTIALLY INDEPENDENT OF THE PH, COMPOUNDS COMPRISING THE SAME, AND USES THEREOF  
The present invention relates to amino acid sequences that bind to serum proteins such as serum albumin essentially independently in the pH range of 5 to 8; to compounds, proteins and polypeptides...
US20080112950 Naturally occurring IgM antibodies that bind lymphocytes  
Human and animal serum contains naturally occurring autoantibodies that develop at birth in absence of deliberate immunization. These antibodies are predominantly of IgM isotype but can include...
US20110110929 HUMAN ANTI-IDIOTYPIC ANTIBODY FRAGMENTS THAT MIMIC HER-2/NEU  
This invention relates to human anti-idiotype antibody fragments, especially scFv, characterized by the ability to mimic Her-2/neu tumor associated antigen. These antibody fragments are promising...
US20070298032 Proteins Involved In Quorum Sensing  
The invention relates to a method of regulating quorum sensing in bacteria by modulating the activation of LuxR or a homologue thereof. Such modulation generally occurs when the bacteria are in...
US20080233112 Treatment of Diseases  
Methods of treatment of various non-demyelinating and demyelinating neural disorders are provided, comprising administering a serum composition obtained from a goat after challenge with an...
US20100008905 ANTI-IDIOTYPE MONOCLONAL ANTIBODIES AS MIMOTOPES OF THE HIV GP120 ANTIGEN  
Novel anti-idiotype monoclonal antibodies are described which are capable of specifically reacting with the idiotype of human anti-gp120 antibodies, of inhibiting the binding between the gp120...
US20090263380 ANTI-IDIOTYPIC ANTIBODIES NEUTRALIZING THE INHIBITORY ACTIVITY OF AN INHIBITORY ANTIBODY DIRECTED AGAINST THE C1 DOMAIN OF FACTOR VIII  
The present invention is related to a monoclonal anti-idiotypic antibody directed against a Factor VIII inhibitor antibody binding to the C1 domain of Factor VIII, as well as to a cell line...
US20060165675 Modulation of mesenchymal cells via iga-receptors  
IgA receptors, including a polymeric immunoglobulin receptor (pIgR) and a FcαR, have been found on smooth muscle cells, synovial fibroblast cells and on both synovial and endothelial cells in...
US20090285804 Anti-ADDLs antibodies and uses thereof  
The invention herein comprises antibodies that bind to amyloid beta-derived diffusible ligands (ADDLs). ADDLs comprise amyloid β protein assembled into soluble, globular, non-fibrillar, oligomeric...
US20130330323 Rapid Generation of Anti-Idiotypic Antibodies  
In vivo methods for making anti-idiotypic antibodies and compositions comprising the antibodies.
US20070258978 Immunogenic Recombinant Antibody  
The invention refers to an immunogenic recombinant antibody designed for immunization of primates comprising at least a part of a murine IgG2a subtype amino acid sequence and a mammalian...
US20100040605 ANTIBODY IDENTIFYING AN ANTIGEN-BOUND ANTIBODY AND AN ANTIGEN-UNBOUND ANTIBODY, AND METHOD FOR PREPARING THE SAME  
The present invention relates to an antibody that recognizes a first antibody, the antibody specifically recognizing one of a free first antibody and an antigen-binding first antibody. More...
US20100330076 IMMUNOGLOBULIN FC POLYPEPTIDES  
Methods and compositions involving polypeptides having an aglycosylated antibody Fc domain. In certain embodiments, polypeptides have an aglycosylated Fc domain that contains one or more...
US20100297008 GANGLIOSIDE ASSOCIATED RECOMBINANT ANTIBODIES AND THE USE THEREOF IN THE DIAGNOSIS AND TREATMENT OF TUMORS  
The present invention is related with the obtaining of modified antibodies by means of the DNA recombinant technology from the murine monoclonal antibody P3 (MAb P3) produced by the hybridoma cell...
US20070014785 Use of antibodies against CD20 for the treatment of the graft versus host disease  
It is described the use of antibodies against exogenous surface antigens not present on normal human T lymphocytes for the preparation of compositions for the treatment of the graft versus host...

Matches 101 - 150 out of 248 < 1 2 3 4 5 >